Multiple Sclerosis Drugs Market By Molecule (Biologics, Small Molecules), By Route Of Administration Type (Oral Therapeutic Drugs, Parenteral Therapeutic Drugs) - Growth, Share, Opportunities & Competitive Analysis, 2017 – 2025

Multiple sclerosis (MS) is a chronic demyelinating inflammatory disease of the central nervous system. It is the most common neurological disease in adults and women. The global multiple sclerosis drugs market is rapidly growing due to factors such as growing prevalence of MS, significant unmet needs, and promising pipeline molecules.  

The report titled “Multiple Sclerosis Drugs Market - Growth, Future Prospects and Competitive Analysis, 2017–2025” offers strategic insights into the overall multiple sclerosis drugs market along with the market size and estimates for the duration 2015 to 2025. The research study covers in-depth analysis of market segments based on molecule type (biologics and small molecules), route of administration (oral therapeutic drugs, parenteral therapeutic drugs) and different geographical regions.

Geographically, the global multiple sclerosis drugs market is studied for the following regional markets:  

• North America
  • U.S.
  • Canada
• Europe
  • U.K.
  • Germany
  • Rest of Europe
• Asia-Pacific
  • China
  • Japan
  • Rest of Asia Pacific
• Latin America
  • Brazil
  • Mexico
  • Rest of LATAM
• Middle East and Africa
  • GCC
  • Rest of MEA

Market size and forecast for these regional and country level markets are presented in this study for the period 2015-2025. Market growth rates for the forecast period 2017-2025 are also included in this report, considering 2016 as the base year.

Along with quantitative information, qualitative information sets and assessment tools are provided in this study for better analysis of the overall market scenario, pipeline analysis and future prospects. Information such as market inclination insights and drivers, challenges and opportunities assists the readers for understanding the ongoing trends in the global multiple sclerosis drugs market. Tools such as market positioning of key players and attractive investment proposition provide the readers with insights on the competitive scenario of the global multiple sclerosis drugs market. This report concludes with company profiles section that highlights major information about the key players engaged in global multiple sclerosis drugs market. In-depth competitive environment analysis and historical years (2015) market size data are also provided in the report.      

Thus, the research study provides a holistic view of the global multiple sclerosis drugs market, offering market size and estimates for the period from 2015 to 2025, keeping in mind the above-mentioned factors.

For the purpose of this study, the global multiple sclerosis drugs market is categorized into:

• North America
• Europe
• Asia Pacific
• Latin America (LATAM)
• Middle East and Africa (MEA)

In the base year 2016, North America dominated the multiple sclerosis drugs market and it is estimated to show fastest market growth during forecast period. Some factors such as increasing incidence of MS, technological advances, upsurge in funding by government agencies and private organizations in healthcare system and higher cost of treatment medication are prime factors that fueling the growth of multiple sclerosis drugs market in North America. According to the Multiple Sclerosis Foundation, more than 400,000 people in the United States and about 2.5 million people around the world have MS; about 200 new cases are diagnosed each week in the United States. MS is an expensive disease to treat; it is studied that direct and indirect health care costs range from US$ 8,528 to US$ 54,244 per patient per year in the United States. Europe is the second largest revenue generating regional market for multiple sclerosis. Existence of higher number of target population is driving the market growth in Europe. The Multiple Sclerosis Foundation estimates that the incidence of MS is higher in colder climates, people of Northern European descent have the highest risk of developing MS, no matter where they live.